The prognostic ability of PGG for multiple long term clinical endpoints was examined using Cox models. Interactions between PGG and race were tested.
INTRODUCTION AND OBJECTIVES:
Comorbidities are medical disorders co-existing in patients with prostate cancer (PCa). Comorbidity, like PCa, is age-related and prevalent, influencing treatment choices. Although comorbidity may adversely affect competing-cause mortality in PCa patients, the impact on PCa-specific mortality is not known.
METHODS: Using the PcBaSe Sweden composite population-based dataset, 118543 men diagnosed with PCa between 1998 and 2012, and followed up for survival until 2014 were identified. Median follow-up was 8.3 (IQR¼5.2-11.5) years to death from PCa or other causes. RESULTS: In the complete unadjusted dataset, an effect of increasing comorbidity was observed on PCa-specific and othercause mortality. Following adjustments for patient and tumour characteristics, the effect of comorbidity on PCa-specific mortality was lost, while maintained for other-cause mortality. Following additional adjustment for treatment type, an effect of comorbidity on PCaspecific mortality was not observed, while present for other-cause mortality.
CONCLUSIONS: During the study period in Sweden, comorbidity appeared to affect other-cause, but not PCa-specific, mortality after accounting for patient and tumour characteristics, and treatment type. Increasing comorbidity did not impact on PCa-specific mortality irrespective of radical treatment (RP or RT). Consequently, in population-based comparative PCa treatment effectiveness studies, the differences in oncological outcomes may not be due to the varying distribution of comorbidity among treatment groups, hence comorbidity is unlikely to be a confounder. database, we sought to determine the effect of recent USPSTF recommendations on prostate cancer incidence based on Gleason score (GS), and to identify differences in GS based on race.
METHODS: SEER database was analyzed from 2008-2013. Patients were divided based on recorded race. GS were stratified as low (2-6), intermediate (7) or high (8-10). Incidence was compared between 2008 and 2013 by determining incidence rate ratio (IRR) and annual percentage change (APC). Statistical analysis was performed with SEERSTAT and excel, confidence interval was set at 95%, with p< 0.05 as significant. RESULTS: 337,504 patients diagnosed with prostate cancer within SEER 18 between 2008 and 2013 were included in the analysis. The mean age range was between 65-74 years. Majority (68.1%) of patients were White, followed by 14.6% Black. GS 2-6 was recorded for 41.8%, followed by GS 7 in 36.2% of patients, and GS 8-10 in 15.9% of patients. Cumulative six year GS 2-6 incidence was noted to be 76.2, 52.9, 44.7 and 25.0 per 100,000 for Black (B), White (W), Hispanic (H), and Asian/Pacific Islanders (API), respectively. GS 7 incidences were 81.3, 46.4, 36.2 and 23.4 per 100,000 for B, W, H, and API, respectively. GS 8-10 was reported in 37.5, 21.0, 21.7 and 18.0 per 100,000 for B, W, H, and API, respectively. The IRR demonstrated a decline in incidence across races and Gleason scores. Between 2008 and 2013 GS 7 IRRs were 0.74 B, 0.65 W, 0.61 H, 0.60 API and GS 8-10 IRRs were 0.85 B, 0.89 W, 0.83 H, 0.78 API. APC significantly declined among all races for GS [2] [3] [4] [5] [6] and GS 7 . Additionally, APC significantly declined for B and H GS 8-10 (-3.51 B, -4.39 H). APC of GS 8-10 incidence showed no statistically significant increase or decline for W and API (-2.28 W, -5.05 API).
CONCLUSIONS: Analysis of SEER demonstrates a decline in incidence of prostate cancer among all races. Notably, there was a decline in GS 8-10 prostate cancer incidence for B, W, H, and API groups, suggesting reduced diagnosis of aggressive prostate cancer in the USPSTF guideline era. Vol. 197, No. 4S, Supplement, Friday, May 12, 2017 THE JOURNAL OF UROLOGY â e61
